Followers | 898 |
Posts | 148964 |
Boards Moderated | 0 |
Alias Born | 08/13/2010 |
Tuesday, November 07, 2017 12:32:30 PM
In addition, the condition of two of the Company’s oldest fermentation vessels may limit the Company’s ability to co-produce isobutanol and ethanol (for more information, see the Luverne Facility Update section in the Company’s Form 10-Q for the Quarter ended September 30, 2017). The Company does expect to produce any more isobutanol during 2017. Going forward, the Company expects its operating strategy will be to focus on the production of ethanol and to produce limited volumes of isobutanol until the completion of the Luverne Facility Expansion or until the Company has repaired or replaced one or both of two older fermentation vessels.
During the third quarter of 2017, the Company sold limited quantities of isobutanol and renewable hydrocarbons (ATJ, isooctane and isooctene). In the quarter, the Company’s isobutanol market development efforts were focused on gaining market acceptance in its core gasoline blendstock markets such as marinas and on-road gasoline fueling stations, while maintaining its targeted selling price. The Company continued to work with its distribution partners to make investments to develop end-customer relationships, as well as to establish value chains to deliver its isobutanol to those end-customers. The Company believes that gasoline end users such as boat owners and car owners remain interested in purchasing isobutanol containing gasoline because of the improved properties compared to ethanol containing gasoline. The demand for the Company’s renewable isobutanol, in terms of the number of retail pumps selling isobutanol-blended finished gasoline in Houston and other markets, has grown rapidly during 2017. However, given the low number of pumps that were selling isobutanol-blended gasoline at the beginning of 2017, limited quantities of isobutanol have been sold during 2017. The Company expects that sales of the Company’s isobutanol will increase in 2018 as the markets for isobutanol-blended finished gasoline further develop.
Gevo’s market development efforts related to its renewable hydrocarbon products were mainly targeted towards entering into binding supply agreements to underpin the economics of the Luverne Facility Expansion that Gevo plans to construct. Gevo has been in discussions with numerous potential ATJ and isooctane customers to enter into long term supply agreements, with a goal of signing contracts representing the majority of the isobutanol production volumes to be produced at the expanded Luverne Facility. Currently, Gevo is discussing or negotiating terms for long-term supply agreements with two large potential customers. There can be no assurances that these discussions or negotiations will result in definitive binding agreements.
As Gevo develops markets for its products, there will be a mismatch in timing between isobutanol production and sales. As a result, at times Gevo will build isobutanol inventory levels. At September 30, 2017, Gevo had approximately 350,000 gallons of isobutanol and approximately 54,000 gallons of renewable hydrocarbons in inventory.
Also, during the third quarter of 2017, Gevo produced and sold approximately 4.2 million of ethanol.
Nothing I say, post, or do should ever be considered financial advice. I may be holding a long, short or no position. I am NOT or NEVER have I been compensated to post on here or anywhere and all my posts are for entertainment purposes only.
Recent GEVO News
- Gevo Reports First Quarter 2024 Financial Results • GlobeNewswire Inc. • 05/02/2024 08:01:00 PM
- Gevo’s Sustainable Aviation Fuel Well-Positioned in Light of New Guidance from Treasury Department • GlobeNewswire Inc. • 04/30/2024 08:58:47 PM
- Gevo to Report First Quarter 2024 Financial Results on May 2, 2024 • GlobeNewswire Inc. • 04/17/2024 08:30:00 PM
- Gevo RNG Subsidiary Successfully Remarkets Its Tax-Exempt Green Bonds • GlobeNewswire Inc. • 04/01/2024 08:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 09:03:50 PM
- Gevo Reports Fourth Quarter and Full Year 2023 Financial Results • GlobeNewswire Inc. • 03/07/2024 09:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/04/2024 09:05:32 PM
- Gevo Hires Damien Perriman as Chief Business Development Officer • GlobeNewswire Inc. • 02/26/2024 02:00:00 PM
- Gevo to Participate in Upcoming Virtual Investor Meetings • GlobeNewswire Inc. • 02/08/2024 06:00:00 PM
- Gevo to Report Fourth Quarter 2023 Financial Results on March 7, 2024 • GlobeNewswire Inc. • 02/08/2024 02:01:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/05/2024 05:15:22 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/24/2024 02:10:11 PM
- Gevo Provides Business Update • GlobeNewswire Inc. • 01/24/2024 02:05:00 PM
- Gevo Files New S-3 Ahead of Expiration, Updates ATM Agreement • GlobeNewswire Inc. • 01/16/2024 09:01:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 01/16/2024 02:05:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/03/2024 09:12:45 PM
- Gevo Announces Appointment of Katie Ellet to Board of Directors • GlobeNewswire Inc. • 01/03/2024 09:05:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 12/26/2023 09:47:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/26/2023 09:33:10 PM
- Gevo VP of Government Relations Lindsay Fitzgerald and VP of Finance & Strategy Eric Frey to Participate in a Water Tower Research Fireside Chat on Tuesday, December 19th at 10:00 am ET • GlobeNewswire Inc. • 12/18/2023 02:00:00 PM
- Gevo Statement on Treasury Guidance for SAF Tax Credit • GlobeNewswire Inc. • 12/15/2023 03:19:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/13/2023 09:48:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/13/2023 09:34:17 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 12/12/2023 09:07:08 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM